New Study In Pediatrics Shows Nitric Oxide Therapy For Newborns Effective And Cost Saving
PITTSBURGH, December 8, 2003 An inhaled treatment for critically ill newborns is less invasive, more effective and costs less than the treatment that traditionally has been used to treat a potentially fatal condition called hypoxic respiratory failure (HRF), according to a study published today in the journal Pediatrics.
The study focuses on the positive effects of inhaled nitric oxide for the treatment of HRF and reveals a rarity in today's world of rising medical costs: a breakthrough treatment that benefits patients and is less expensive than the standard treatment.
Its almost unprecedented to hear of an advanced medication that actually saves money compared with an older treatment, said Derek C. Angus, M.D., professor of critical care medicine at the University of Pittsburgh School of Medicine, the study's lead author and director of the Clinical Research, Investigation and Systems Modeling of Acute Illness (CRISMA) laboratory at the University of Pittsburgh. When you are treating a critically ill baby, you want the best treatment available no matter what the cost. Its heartening to learn that in the case of babies with hypoxic respiratory failure, we can offer state-of-the-art treatment that improves outcomes in comparison to traditional care and does so at potentially reduced costs overall.
HRF develops in newborns whose lungs cannot deliver enough oxygen to their bodies, causing them to appear bluish and endangers their lives. The condition often appears on the first day after birth, and affects about 30,000 full-term and near-term infants each year. There is no prenatal test or other way to predict which infants will develop HRF, so there is no known way to prevent the condition.
In the past, the only effective treatment for newborns with HRF who did not respond to artificial ventilation and supplemental oxygen was an invasive surgical procedure known as extracorporeal membrane oxygenation (ECMO), which involves cutting a newborns jugular vein and putting the baby on a heart-lung machine to oxygenate the blood. Besides being invasive, the procedure has the potential to cause severe complications.
Nitric oxide, by contrast, is administered as an inhaled gas, and has few potential complications. But while hospital stays involving ECMO are reimbursed by private and government insurance plans, experts say that reimbursement for inhaled nitric oxide traditionally has been inadequate. This is based in large part on the fact that it is a newer treatment than ECMO, and thus reimbursement policies have not caught up to the fact that the therapy is now more widely used.
Many therapies and life-saving equipment readily accepted by society are quite costly, said Maria Hardin, vice president of patient services for the National Organization for Rare Disorders (NORD). Perhaps now that we have hard data on the cost savings this treatment provides, insurers will do a better job of covering it.
Key Study Findings
The new study shows that inhaled nitric oxide actually saves a significant amount of money when compared with the older and more invasive ECMO procedure:
For every 100 newborns with HRF, treatment with inhaled nitric oxide resulted in a cost savings of more than $440,000. This savings occurred among newborns who did not need to be transferred to another hospital for ECMO treatment.
Much of the cost savings stems from the avoidance of ECMO, a costly surgical procedure.
Treating newborns with inhaled nitric oxide at local hospitals (rather than higher-level hospitals that also provide ECMO) was most cost-effective, because when the treatment prevented the need for ECMO, it also prevented the cost of transferring the baby to the ECMO center.
Using the data from two randomized controlled trials and other real-life experiences with ECMO and inhaled nitric oxide, researchers at the University of Pittsburgh's CRISMA laboratory developed a cost-effectiveness model that estimated treatment outcomes and costs associated with treatment and recovery. The researchers looked at two scenarios: a base case where babies were transferred to advanced-care hospitals where ECMO was available, and a reference case, where nitric oxide therapy was administered at local hospitals. Both scenarios suggested that nitric oxide therapy was cheaper and more effective than ECMO. The base case study showed a savings of $1,880 per case, while the reference case showed an even higher savings $4,400 per case.
We now have strong evidence that I think will surprise many physicians and hospitals, Dr. Angus said. Hopefully, this will encourage everyone to take a new look at just how important this therapy is.
In December 1999, the U.S. Food and Drug Administration (FDA) approved nitric oxide for inhalation (marketed under the trade name INOmax) used in conjunction with ventilatory support and other appropriate agents, for the treatment of term and near-term (>34 weeks) neonates with HRF associated with clinical or echocardiographic evidence of pulmonary hypertension (high blood pressure in the lungs). The drug works by relaxing smooth-muscle cells in blood-vessel walls in the lungs, allowing the lungs to properly oxygenate the blood and provide it to the rest of the body. This study was supported in part by a grant from INO Therapeutics, Inc., which manufactures INOmax.